Tresiba Flex Pen 5*3 Ml

Tresiba FlexTouch Pen 100 Units/mL (Insulin Degludec) – 5 x 3 mL Prefilled Pens

Drug Overview

Tresiba FlexTouch Pen is a long-acting basal insulin designed to provide stable and consistent blood glucose control in patients with diabetes mellitus. Containing insulin degludec, this ultra-long-acting insulin offers extended duration of action, making it suitable for once-daily use. Tresiba FlexTouch Pen helps maintain steady glucose levels and reduces fluctuations throughout the day.

Active Ingredient and Composition

• Active ingredient: Insulin Degludec
• Strength: 100 units/mL
• Dosage form: Solution for subcutaneous injection in a prefilled pen
• Pack size: 5 pens, each containing 3 mL

Insulin degludec is an ultra-long-acting basal insulin analog that provides prolonged glucose-lowering effects.

Drug Class

• Long-Acting Basal Insulin (Insulin Analog)

Uses and Medical Indications of Tresiba FlexTouch Pen

Tresiba FlexTouch Pen is indicated for:

• Diabetes mellitus (Type 1 and Type 2):
  • Improves long-term blood glucose control
  • Provides consistent basal insulin coverage

It is commonly used as part of a comprehensive diabetes management plan, including diet, exercise, and additional medications if required.

How Tresiba FlexTouch Pen Works

Insulin degludec forms multi-hexamers under the skin after injection, resulting in:

• Slow and continuous insulin release
• Stable glucose-lowering effect over 24 hours or longer
• Reduced risk of glucose variability

This mechanism ensures steady basal insulin levels, helping to maintain optimal glycemic control.

Dosage and Administration

• Administered once daily via subcutaneous injection
• Can be injected at any time of day, preferably at the same time daily
• Injection sites include the abdomen, thigh, or upper arm
• Dose is individualized based on patient needs and glucose levels

Always follow your healthcare provider’s instructions and adjust doses only under medical supervision.

Possible Side Effects of Tresiba FlexTouch Pen

Common side effects include:

• Hypoglycemia (low blood sugar)
• Weight gain
• Injection site reactions (redness, irritation)

Rare side effects:

• Allergic reactions

Immediate medical attention is required if severe hypoglycemia or allergic symptoms occur.

Contraindications

• Hypersensitivity to insulin degludec or any component of the formulation
• Episodes of hypoglycemia

Drug Interactions

Tresiba FlexTouch Pen may interact with:

• Other antidiabetic medications
• Beta-blockers (may mask hypoglycemia symptoms)
• Corticosteroids and certain hormones affecting glucose levels

Always inform your healthcare provider about all medications you are using.

Warnings and Precautions

• Use only under medical supervision
• Monitor blood glucose levels regularly
• Adjust dose carefully to avoid hypoglycemia
• Rotate injection sites to prevent lipodystrophy

Use During Pregnancy and Breastfeeding

• May be used under medical supervision
• Insulin requirements may change during pregnancy
• Consult your doctor before breastfeeding

Use for Children

• Can be used in children with diabetes under specialist supervision

Drug Alternatives

• Insulin Glargine (Lantus)
• Insulin Detemir (Levemir)
• Rapid-acting insulin (e.g., NovoRapid) for mealtime control

Comparison With Similar Drugs

• Tresiba FlexTouch Pen provides longer duration of action compared to insulin glargine
• Offers more stable glucose control with less variability
• Rapid-acting insulins like NovoRapid are used for meals, while Tresiba covers basal needs

Safe Usage Tips

• Store in a refrigerator at 2–8°C (do not freeze)
• After opening, can be stored at room temperature for a limited period
• Follow proper injection technique
• Maintain a healthy diet and regular physical activity

Conclusion

Tresiba FlexTouch Pen is an advanced long-acting insulin that provides reliable and stable blood sugar control for patients with diabetes. Its extended duration and flexible dosing make it an essential component of modern diabetes management when used under medical supervision.